AFC
CRL icon

Ares Financial Consulting’s Charles River Laboratories CRL Stock Holding History

Ares Financial Consulting’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$680 Hold
3
– – ﹤0.01% 1060
2026
Q1 		$525 Hold
3
– – ﹤0.01% 1015
2025
Q4 		$598 Buy
+3
New +$544 ﹤0.01% 834

Other funds holding CRL

CB
Cooke & Bieler Philadelphia, Pennsylvania $8.65B AUM 9.66% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
VBA
Van Berkom & Associates Montreal, Quebec, Canada $3.1B AUM 12.88% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
CIM
Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.47B AUM 16.96% 1-Year Est. Return

Ares Financial Consulting's CRL Position: Q2 2026 in Review

Ares Financial Consulting held its Charles River Laboratories (CRL) position steady in Q2 2026 at 3 shares worth $680. The position accounts for ﹤0.01% of the portfolio, ranked #1060.

Ares Financial Consulting first reported a position in CRL in Q4 2025 and has held it in 3 quarters since. 215 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Ares Financial Consulting held 3 shares of Charles River Laboratories worth $680 as of Q2 2026.
  • Ares Financial Consulting left its Charles River Laboratories share count unchanged in Q2 2026.
  • Charles River Laboratories made up ﹤0.01% of Ares Financial Consulting's portfolio in Q2 2026, its #1060 holding.
  • Ares Financial Consulting first reported a position in Charles River Laboratories in Q4 2025 and has held it in 3 quarters since.
  • 215 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.